Balance Sheet
Cash Flow Statement
AmortizationAmortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Net Income (2023 - 2025)

Historic Net Income for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$1.9 million.

  • BioLineRx's Net Income rose 4941.52% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.8 million, marking a year-over-year increase of 5725.76%. This contributed to the annual value of -$19.3 million for FY2024, which is 5942.77% up from last year.
  • According to the latest figures from Q3 2025, BioLineRx's Net Income is -$1.9 million, which was up 4941.52% from -$2.0 million recorded in Q2 2025.
  • BioLineRx's 5-year Net Income high stood at -$1.9 million for Q3 2025, and its period low was -$19.5 million during Q4 2023.
  • For the 3-year period, BioLineRx's Net Income averaged around -$6.7 million, with its median value being -$5.4 million (2024).
  • Over the last 5 years, BioLineRx's Net Income had its largest YoY gain of 6734.38% in 2024, and its largest YoY loss of 3149.2% in 2024.
  • BioLineRx's Net Income (Quarter) stood at -$19.5 million in 2023, then skyrocketed by 59.28% to -$7.9 million in 2024, then skyrocketed by 76.03% to -$1.9 million in 2025.
  • Its Net Income stands at -$1.9 million for Q3 2025, versus -$2.0 million for Q2 2025 and -$2.0 million for Q1 2025.